
The Indian Council of Medical Research (ICMR) conducted a seven-year follow-up study on 303 healthy male volunteers, revealing the safety and effectiveness of RISUG (Reversible Inhibition of Sperm under Guidance), a non-hormonal injectable male contraceptive. In the open-labeled and non-randomized phase-III study, men aged 25-40 received 60 mg of RISUG, leading to 99.02% effective pregnancy prevention and 97.3% azoospermia. RISUG, involving the injection of a polymeric agent, styrene maleic anhydride (SMA), in di-methyl sulphoxide (DMSO) into the sperm duct, was developed by Dr. Sujoy Kumar Guha of IIT Kharagpur. The study found no serious side effects and no adverse effects on the volunteers' wives, providing hope for a viable male contraceptive option.
Like
Save
Share